Benchmark Reiterates Speculative Buy on Nephros, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman has reiterated a Speculative Buy rating on Nephros (NASDAQ:NEPH) and maintained a $5 price target.
May 15, 2024 | 11:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Robert Wasserman has reiterated a Speculative Buy rating on Nephros and maintained a $5 price target. This suggests confidence in the company's potential growth.
The reiteration of a Speculative Buy rating and the maintenance of a $5 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100